Ok, now that the dead cat bounce is over it's time to short and standby for the next two failed trials to report in so we can officially move on. That is just how it goes in the biopharma business. Not all drugs are winners. I was long but now realistic.
the bounce didnt even started shorty.. are you nervous?
have you ever looked at fundamentals? net cash? no debt? strong pipeline? catalysts ahead?
you have chosen bad stock to bash and you will be burned badly